首页> 外文OA文献 >BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma

【2h】

BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma

机译：BRAF融合作为BRAFV600E突变体黑素瘤的vemureafenib的一种新机制

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Atul Kulkarni; Husam Al-Hraishawi; Srilatha Simhadri; Kim M. Hirshfield; Suzie Chen; Sharon Pine; Chandrika Jeyamohan; Levi Sokol; Siraj Ali; Man Lung Teo; Eileen White; Lorna Rodriguez-Rodriguez; Janice M. Mehnert; Shridar Ganesan;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAF(V600E) Mutant Melanoma [J] . Kulkarni Atul, Al-Hraishawi Husam, Simhadri Srilatha, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第18期

机译：BRAF融合作为BRAF（V600E）突变体黑素瘤的vemureafenib抗性的新机制
2. Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells [J] . Teresa Delgado-Go?i, Teresa Casals Galobart, Slawomir Wantuch, British Journal of Cancer . 2020,第1期

机译：增加的炎症性脂质代谢和翼状化线粒体激活遵循在<斜体> BRAF - 矫正黑素瘤细胞中的抗vemurafenib的抗性
3. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAF(V600E) Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice [J] . Feng Jia-Hua, Nakagawa-Goto Kyoko, Lee Kuo-Hsiung, Molecular cancer therapeutics . 2016,第6期

机译：新型植物倍半萜烯内酯衍生物DETD-35抑制BRAF（V600E）突变型黑色素瘤生长并克服小鼠获得的维罗非尼耐药性
4. Overcoming Acquired Resistance in BRAFV600 Melanoma Using a Combination of ABI-274 and Vemurafenib in a Predictive A375RF21Model [C] . Wei Li, Jin Wang, Jianjun Chen, Molecular Medicine TRI-CON. . 2014

机译：使用ABI-274和VemureaFenib的组合在预测A375RF21MODEL中克服BRAF V600黑素瘤的耐受性
5. Mechanisms Underlying RAF Inhibitor Resistance by BRAF Splice Variants in Melanoma [D] . Vido, Michael J. 2020

机译：黑色瘤中BRAF均含量抗性的机制抑制剂抗性
6. A novel plant sesquiterpene lactone derivative DETD-35 suppresses BRAFV600E mutant melanoma growth and overcomes acquired vemurafenib resistance in mice [O] . Jia-Hua Feng, Kyoko Nakagawa-Goto, Kuo-Hsiung Lee, -1

机译：一种新型的植物倍半萜内酯衍生物DETD-35抑制BRAFV600E突变型黑色素瘤生长并克服小鼠中获得的维罗非尼耐药性
7. FDG-PET is a good biomarker of both early response and acquired resistance in BRAF mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973 [O] . 2012

机译：FDG-PET是用vemurafenib和MEK抑制剂GDC-0973治疗的BRAF突变型黑色素瘤的早期反应和获得性耐药的良好生物标志物
8. Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR Mutant and ALK Positive Lung Cancers. [R] . Sequist, L., Engelman, J. 2016

机译：缺乏BIm表达作为EGFR突变体和aLK阳性肺癌中靶向治疗的内在和获得性抗性的机制。

BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma

著录项

引文网络

相似文献

相关主题

期刊订阅